GemPharmatech Co., Ltd. (SHA:688046)

9.91% (1Y)

Market Cap	5.20B
Revenue (ttm)	700.61M
Net Income (ttm)	110.32M
Shares Out	407.41M
EPS (ttm)	0.27
PE Ratio	47.25
Forward PE	31.90
Dividend	0.14 (1.09%)
Ex-Dividend Date	Nov 4, 2024

Volume	5,761,826
Average Volume	4,653,345
Open	12.90
Previous Close	12.88
Day's Range	12.59 - 13.14
52-Week Range	9.08 - 17.70
Beta	0.49
RSI	57.84
Earnings Date	Aug 29, 2025

About GemPharmatech

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other se...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,578
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688046

Financial Performance

In 2024, GemPharmatech's revenue was 686.84 million, an increase of 10.39% compared to the previous year's 622.19 million. Earnings were 109.82 million, a decrease of -30.89%.